Biotech Jason Mast STAT Plus: Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb
Pharma Matthew Herper, Eric Boodman, Andrew Joseph, Lizzy Lawrence, Adam Feuerstein, and Jason Mast STAT Plus: What the withdrawal of its sickle cell drug means for Pfizer, patients, and the FDA
Biotech Adam Feuerstein and Jason Mast STAT Plus: Pfizer pulls sickle cell treatment Oxbryta off global markets
Biotech Brittany Trang and Jason Mast STAT Plus: Ginkgo Bioworks bets on protein AI model and data generation to turn struggling company around
Politics John Wilkerson and Jason Mast STAT Plus: House panel passes pediatric rare disease bill, setting it up for government funding bill
Biotech Jason Mast STAT Plus: In race to make gene therapy for age-related blindness, 4D Molecular announces positive results
Biotech Matthew Herper and Jason Mast STAT Plus: Moderna touts research progress as it cuts R&D spending by $1.1 billion
Biotech Jason Mast and John Wilkerson STAT Plus: A rare disease program, portrayed as both lifeline and pharma handout, is set to expire
Biotech Jason Mast STAT Plus: Drug aimed at strengthening neurons to treat Alzheimer’s fails in trial
Exclusive Jason Mast STAT Plus: Biden administration’s $3.2 billion antiviral pandemic plan is fizzling out
Exclusive Jason Mast and Allison DeAngelis STAT Plus: Tome Biosciences, once a high-flying gene-editing startup, is floundering
Biotech Jason Mast STAT Plus: Early data from Lexeo’s gene therapy for rare heart disease shows promise
